Mette Gyldenløve1, Heidi Storgaard2, Jens J Holst3, Tina Vilsbøll2, Filip K Knop4, Lone Skov5. 1. Department of Dermato-Allergology, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark. Electronic address: mette.gyldenloeve@regionh.dk. 2. Center for Diabetes Research, Department of Medicine, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark. 3. Novo Nordisk Foundation (NNF) Center for Basic Metabolic Research, Department of Biomedicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. 4. Center for Diabetes Research, Department of Medicine, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark; Novo Nordisk Foundation (NNF) Center for Basic Metabolic Research, Department of Biomedicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. 5. Department of Dermato-Allergology, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.
Abstract
BACKGROUND: Patients with psoriasis have increased risk of type 2 diabetes. The pathophysiology is largely unknown, but it is hypothesized that systemic inflammation causes insulin resistance. Insulin sensitivity has only been sparsely investigated in patients with psoriasis, and previous studies have used suboptimal methodology. The hyperinsulinemic euglycemic clamp remains the gold standard for quantifying whole-body insulin sensitivity. OBJECTIVE: We sought to investigate if normal glucose-tolerant patients with psoriasis exhibit impaired insulin sensitivity. METHODS: Three-hour hyperinsulinemic euglycemic clamps were performed in 16 patients with moderate to severe, untreated psoriasis and 16 matched control subjects. RESULTS: The 2 groups were similar with regard to age, gender, body mass index, body composition, physical activity, fasting plasma glucose, and glycosylated hemoglobin. Mean ± SEM psoriasis duration was 23 ± 3 years and Psoriasis Area and Severity Index score was 12.7 ± 1.4. Patients with psoriasis exhibited reduced insulin sensitivity compared with control subjects (median M-value 4.5 [range 1.6-14.0] vs 7.4 [range 2.1-10.8] mg/kg/min, P = .046). There were no differences between groups in plasma glucose, insulin, C-peptide, and glucagon during the clamp. LIMITATIONS: The classic hyperinsulinemic euglycemic clamp technique does not allow assessment of endogenous glucose production. CONCLUSION: Patients with psoriasis were more insulin resistant compared with healthy control subjects. This supports that psoriasis may be a prediabetic condition.
BACKGROUND:Patients with psoriasis have increased risk of type 2 diabetes. The pathophysiology is largely unknown, but it is hypothesized that systemic inflammation causes insulin resistance. Insulin sensitivity has only been sparsely investigated in patients with psoriasis, and previous studies have used suboptimal methodology. The hyperinsulinemic euglycemic clamp remains the gold standard for quantifying whole-body insulin sensitivity. OBJECTIVE: We sought to investigate if normal glucose-tolerant patients with psoriasis exhibit impaired insulin sensitivity. METHODS: Three-hour hyperinsulinemic euglycemic clamps were performed in 16 patients with moderate to severe, untreated psoriasis and 16 matched control subjects. RESULTS: The 2 groups were similar with regard to age, gender, body mass index, body composition, physical activity, fasting plasma glucose, and glycosylated hemoglobin. Mean ± SEM psoriasis duration was 23 ± 3 years and Psoriasis Area and Severity Index score was 12.7 ± 1.4. Patients with psoriasis exhibited reduced insulin sensitivity compared with control subjects (median M-value 4.5 [range 1.6-14.0] vs 7.4 [range 2.1-10.8] mg/kg/min, P = .046). There were no differences between groups in plasma glucose, insulin, C-peptide, and glucagon during the clamp. LIMITATIONS: The classic hyperinsulinemic euglycemic clamp technique does not allow assessment of endogenous glucose production. CONCLUSION:Patients with psoriasis were more insulin resistant compared with healthy control subjects. This supports that psoriasis may be a prediabetic condition.
Authors: Alexander Egeberg; Lone Skov; Aditya A Joshi; Lotus Mallbris; Gunnar H Gislason; Jashin J Wu; Justin Rodante; Joseph B Lerman; Mark A Ahlman; Joel M Gelfand; Nehal N Mehta Journal: J Am Acad Dermatol Date: 2017-08-18 Impact factor: 11.527
Authors: Charlotte L Harrington; Amit K Dey; Raza Yunus; Aditya A Joshi; Nehal N Mehta Journal: Am J Physiol Heart Circ Physiol Date: 2017-03-03 Impact factor: 4.733
Authors: Milena Aksentijevich; Sundus S Lateef; Paula Anzenberg; Amit K Dey; Nehal N Mehta Journal: Trends Cardiovasc Med Date: 2019-11-20 Impact factor: 6.677
Authors: Anke Schwandt; Dominik Bergis; Albrecht Dapp; Stefan Ebner; Peter M Jehle; Stefan Köppen; Alexander Risse; Stefan Zimny; Reinhard W Holl Journal: J Diabetes Res Date: 2015-08-17 Impact factor: 4.011
Authors: Wynnis L Tom; Martin P Playford; Shehla Admani; Balaji Natarajan; Aditya A Joshi; Lawrence F Eichenfield; Nehal N Mehta Journal: J Invest Dermatol Date: 2016-01 Impact factor: 8.551